Abstract
The development and implementation of CAR-T cells warrant ethical vigilance. This attention concerns both the conditions for evaluating these therapies in the context of clinical studies, the acceptable risks in the preference given to innovation regarding other reference therapies, the ability to develop manufacturing sectors in a public framework continuing the decisive contribution of academic research to these innovative concepts, also the negotiation of the “fair price” of treatments when drug companies offer prices considered excessive.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
